血液巨噬细胞中的载脂蛋白10（Apo10）和转酮醇酶样蛋白1（TKTL1）作为可手术乳腺癌早期诊断的潜在生物标志物。

Apo10 and TKTL1 in blood macrophages as potential biomarkers for early diagnosis of operable breast cancer.

作者信息

Wu Minqing, Huang Qiyu, Zhang Lijuan, Liu Yuying, Zeng Musheng, Xie Chuanbo

机构信息

Cancer Prevention Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfengdong Road, Yuexiu District, Guangzhou, 510060, Guangdong, China.

School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi, China.

出版信息

Breast Cancer Res Treat. 2025 Apr;210(2):337-345. doi: 10.1007/s10549-024-07569-3. Epub 2024 Dec 7.

DOI:10.1007/s10549-024-07569-3

PMID:39644404

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11930865/

Abstract

OBJECTIVE

Blood macrophage Apo10 and TKTL1 detection is a novel, noninvasive cancer screening approach, but its relevance in breast cancer remains uncertain. We compared the potential diagnostic value of Apo10 and TKTL1 with commonly used tumor markers in differentiating breast cancer patients.

METHODS

Physical examination and blood sample data from breast cancer patients who did not receive surgery or chemotherapy (retrospective; breast cancer group) and those with benign breast nodules and completely healthy subjects (prospective; control group) were collected from October 2020 to July 2022 at Sun Yat-sen University. Descriptive statistics and receiver operating characteristic (ROC) curves were generated. The area under the ROC curve (AUROC) was calculated to compare the diagnostic efficiency of Apo10 and TKTL1 with conventional biomarkers (carcinoembryonic antigen [CEA], cancer antigens [CA-125, CA-199, CA-153]) in differentiating breast cancer from healthy breasts and benign breast nodules.

RESULTS

From October 2020 to July 2022, 153 breast cancer patients (primarily early-stage disease: n = 113 (73.9%) stage I/II) and 153 control participants (benign breast nodules, n = 56; healthy, n = 97) were included in this study. The breast cancer subtypes were mainly invasive ductal carcinoma (92.8%), with a few cases of DCIS (5.9%), infiltrating lobular carcinoma (0.7%), and mucinous carcinoma (0.7%). Notably, Apo10, TKTL1, and Apo10 + TKTL1 (APT) levels were significantly greater in the cancer group than in the control group (P < 0.001), demonstrating high diagnostic value (AUC = 0.901, 0.871, 0.938) that surpassed CA-125, CA-199, CA-153, and CEA. In a subgroup analysis excluding stage III patients, APT-based breast cancer screening was minimally affected, with the AUROC (0.933-0.938) varying by ≤ 1%.

CONCLUSION

Compared with conventional biomarkers, Apo10, TKTL1, and APT showed superior early-stage breast cancer screening efficacy, potentially emerging as a promising marker for discriminating breast cancer from healthy breasts and nontumoral lesions.

摘要

目的

血液巨噬细胞载脂蛋白10（Apo10）和转酮醇酶样蛋白1（TKTL1）检测是一种新型的非侵入性癌症筛查方法，但其在乳腺癌中的相关性仍不确定。我们比较了Apo10和TKTL1与常用肿瘤标志物在鉴别乳腺癌患者方面的潜在诊断价值。

方法

于2020年10月至2022年7月在中山大学收集未接受手术或化疗的乳腺癌患者（回顾性研究；乳腺癌组）以及患有良性乳腺结节的患者和完全健康受试者（前瞻性研究；对照组）的体格检查和血液样本数据。进行描述性统计并绘制受试者工作特征（ROC）曲线。计算ROC曲线下面积（AUROC），以比较Apo10和TKTL1与传统生物标志物（癌胚抗原[CEA]、癌抗原[CA-125、CA-199、CA-153]）在鉴别乳腺癌与健康乳腺及良性乳腺结节方面的诊断效率。

结果

2020年10月至2022年7月，本研究纳入了153例乳腺癌患者（主要为早期疾病：n = 113例（73.9%）为I/II期）和153例对照参与者（良性乳腺结节，n = 56例；健康者，n = 97例）。乳腺癌亚型主要为浸润性导管癌（92.8%），少数为导管原位癌（DCIS，5.9%）、浸润性小叶癌（0.7%）和黏液癌（0.7%）。值得注意的是，癌症组中Apo10、TKTL1以及Apo10+TKTL1（APT）水平显著高于对照组（P < 0.001），显示出较高的诊断价值（AUC = 0.901、0.871、0.938），超过了CA-125、CA-199、CA-153和CEA。在排除III期患者的亚组分析中，基于APT的乳腺癌筛查受影响最小，AUROC（0.933 - 0.938）变化≤1%。